|
MATR3 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.65543143029845E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.29440022536664E-10 |
| Normal-vs-Stage2 |
2.17929999999367E-05 |
| Normal-vs-Stage3 |
3.37599947997091E-11 |
| Normal-vs-Stage4 |
2.1325163857E-12 |
| Stage1-vs-Stage2 |
7.880800E-01 |
| Stage1-vs-Stage3 |
9.678000E-02 |
| Stage1-vs-Stage4 |
1.276500E-03 |
| Stage2-vs-Stage3 |
1.905220E-01 |
| Stage2-vs-Stage4 |
2.794200E-02 |
| Stage3-vs-Stage4 |
1.817950E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.21846976952611E-12 |
| Normal-vs-AfricanAmerican |
2.496000E-03 |
| Normal-vs-Asian |
1.71099999946023E-07 |
| Caucasian-vs-AfricanAmerican |
1.333000E-01 |
| Caucasian-vs-Asian |
6.121000E-01 |
| AfricanAmerican-vs-Asian |
2.871600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.05649949794429E-11 |
| Normal-vs-Female |
1.62510005452532E-11 |
| Male-vs-Female |
3.583000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.44570000415456E-09 |
| Normal-vs-Age(41-60Yrs) |
2.25719998248053E-10 |
| Normal-vs-Age(61-80Yrs) |
3.11679571041168E-11 |
| Normal-vs-Age(81-100Yrs) |
2.259500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.237600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.084770E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.749400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.946000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
8.401400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
8.470800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.272190E-02 |
| Classical-VS-Follicular |
4.130200E-02 |
| Classical-VS-Other |
2.850400E-01 |
| Classical-VS-Normal |
7.46440020904515E-10 |
| Tall-VS-Follicular |
3.549800E-01 |
| Tall-VS-Other |
8.223600E-01 |
| Tall-VS-Normal |
6.77560008099931E-10 |
| Follicular-VS-Other |
8.172800E-01 |
| Follicular-VS-Normal |
4.96240004643766E-09 |
| Other-VS-Normal |
2.120200E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.63359992200185E-10 |
| Normal-vs-N1 |
2.55210297339659E-11 |
| N0-vs-N1 |
1.227650E-01 |
|
|
